Hottest Stocks (Over $10)	Hottest Stocks ($2-$10)	Biggest Losers (Over $10)	Biggest Losers ($2-$10)	Hottest Industries	Hottest Sectors	EPS / Sales Surprises
Enter Ticker Symbol:   Ticker Lookup Company Quote Company Profile Research Summary EPS Consensus Perspective Insider Transactions Price Performance

Enter any portion of the company’s name to find its corresponding ticker symbol:

Search for :

Zacks Company Profile for Celldex Therapeutics, Inc. (CLDX : NSDQ)

• Company Description    CELLDEX THERAPEUTICS is an integrated biopharmaceutical company that applies its comprehensive Precision Targeted Immunotherapy Platform to generate a pipeline of candidates to treat cancer and other difficult-to-treat diseases. Celldex's immunotherapy platform includes a complementary portfolio of monoclonal antibodies, antibody-targeted vaccines and immunomodulators to create novel disease-specific drug candidates. Number of Employees: 198

• Price / Volume Information    Yesterday's Closing Price: $29.37 Daily Weekly Monthly 20 Day Moving Average: 1,694,961 shares Shares Outstanding: 78.53 (millions) Market Capitalization: $2,306.41 (millions) Beta: 0.90 52 Week High: $45.14 52 Week Low: $22.10 Short Interest Ratio:   % Price Change % Price Change Relative to S&P 500 4 Week -5.62% -6.25% 12 Week -21.70% -26.15% Year To Date 8.14% -4.57%

• Address & Contact Information Street Address Phone / Fax Email Address Web URL 53 FRONTAGE ROAD SUITE 220 - HAMPTON,NJ 08827 USA ph: 908-200-7500 fax: 908-454-1911 ir@celldex.com http://www.celldex.com

• General Corporate Information    Officers Anthony S. Marucci - President; Chief Executive Officer and Director Harry H. Penner, Jr. - Chairman and Director Sam Martin - Senior Vice President; Chief Financial Officer and Keith L. Brownlie - Director Cheryl L. Cohen - Director Peer Information Celldex Therapeutics, Inc. (CORR.) Celldex Therapeutics, Inc. (RSPI) Celldex Therapeutics, Inc. (CGXP) Celldex Therapeutics, Inc. (BGEN) Celldex Therapeutics, Inc. (GTBP) Celldex Therapeutics, Inc. (RGRX) Industry / Sector / Ticker Info Analyst Coverage: No Industry Group: MED-BIOMED/GENE Sector: Medical CUSIP: 15117B202 SIC: 2835 Fiscal Year Fiscal Year End: December Last Reported Quarter: 06/01/26 Next Expected EPS Date: 11/09/26 Share - Related Items Shares Outstanding: 78.53 Most Recent Split Date: 2.00 (0.07:1) Beta: 0.90 Market Capitalization: $2,306.41 (millions)

• EPS Information     • Dividend Information Analyst Coverage: No Dividend Yield: 0.00% Current Fiscal Quarter EPS Consensus Estimate: $-1.03 Indicated Annual Dividend: $0.00 Current Fiscal Year EPS Consensus Estimate: $-4.17 Payout Ratio: Number of Estimates in the Fiscal Year Consensus: 5.00 Change In Payout Ratio: Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00 Next EPS Report Date: 11/09/26

• Fundamental Ratios P/E Current FY Estimate: - Trailing 12 Months: - PEG Ratio: - Price Ratios Price/Book: 3.23 Price/Cash Flow: - Price / Sales: - EPS Growth vs. Year Ago Period: -10.59% vs. Previous Quarter: 20.34% Sales Growth vs. Year Ago Period: -96.99% vs. Previous Quarter: 46.67% ROE 09/30/26 - - 06/30/26 - -52.35 03/31/26 - -50.72 ROA 09/30/26 - - 06/30/26 - -47.61 03/31/26 - -46.59 Current Ratio 09/30/26 - - 06/30/26 - 11.82 03/31/26 - 8.92 Quick Ratio 09/30/26 - - 06/30/26 - 11.82 03/31/26 - 8.92 Operating Margin 09/30/26 - - 06/30/26 - - 03/31/26 - - Net Margin 09/30/26 - - 06/30/26 - - 03/31/26 - - Pre-Tax Margin 09/30/26 - - 06/30/26 - -190,220.86 03/31/26 - -32,753.58 Book Value 09/30/26 - - 06/30/26 - 9.10 03/31/26 - 5.81 Inventory Turnover 09/30/26 - - 06/30/26 - - 03/31/26 - - Debt-to-Equity 09/30/26 - - 06/30/26 - 0.00 03/31/26 - 0.00 Debt-to-Capital 09/30/26 - - 06/30/26 - 0.00 03/31/26 - 0.00

Powered by Zacks Investment Research ©